HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: 285/1/H97    most recent 00956.2002v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (31) Citing Articles via Google Scholar Google Scholar Articles by Liu, Q. Articles by Hofmann, P. A. Search for Related Content PubMed PubMed Citation Articles by Liu, Q. Articles by Hofmann, P. A.

Modulation of protein phosphatase 2a by adenosine A₁ receptors in cardiomyocytes: role for p38 MAPK

Department of Physiology, University of Tennessee Health Science Center, Memphis, Tennessee 38163

Submitted 5 November 2002 ; accepted in final form 14 March 2003

	ABSTRACT

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Adenosine A₁ receptor activation causes protein phosphatase 2a (PP2a) activation in ventricular myocytes. This attenuates -adrenergic functional effects in the heart (Liu Q and Hofmann PA. Am J Physiol Heart Circ Physiol 283: H1314–H1321, 2002). The purpose of the present study was to identify the signaling pathway involved in the translocation/activation of PP2a by adenosine A₁ receptors in ventricular myocytes. We found that N⁶-cyclopentyladenosine (CPA; an adenosine A₁ receptor agonist)-induced PP2a translocation was blocked by p38 MAPK inhibition but not by JNK inhibition. CPA increased phosphorylation of p38 MAPK, and this effect was abolished by pertussis toxin and inhibitors of the cGMP pathway. Moreover, CPA-induced PP2a translocation was blocked by inhibition of the cGMP pathway. Guanylyl cyclase activation mimicked the effects of CPA and caused p38 MAPK phosphorylation and PP2a translocation. Finally, CPA-induced dephosphorylations of troponin I and phospholamban were blocked by pertussis toxin and attenuated by p38 MAPK inhibition. These results suggest that adenosine A₁ receptor-mediated PP2a activation uses a pertussis toxin-sensitive G_i protein-guanylyl cyclase-p38 MAPK pathway. This proposed, novel pathway may play a role in acute modulation of cardiac function.

p38 mitogen-activated protein kinase; guanylyl cyclase; G_i protein

PP2a is a type II serine/threonine phosphatase consisting of a catalytic "C" subunit (PP2a-C), a structural "A" subunit, and one of several regulatory "B" subunits. PP2a activities can be regulated by posttranslational modifications of the catalytic subunit by phosphorylation and carboxymethylation (6, 9, 13). In addition, localized PP2a activity can be altered by direct, transient translocation of the heterotrimeric holoenzyme in Hela cells and mast cells (25, 34). Our previous study (24) demonstrated that in cardiomyocytes PP2a activity can also be modulated through carboxymethylation and translocation. However, how PP2a translocation is regulated and what signaling pathway is involved are not well understood.

Recent studies suggest that PP2a can be activated by p38 MAPK in NIH 3T3 cells (39) and neutrophils (1). Activation of p38 MAPK by adenosine has been demonstrated in the perfused rat heart (15). Moreover, the adenosine A₁ receptor agonist N⁶-cyclopentyladenosine (CPA) activates p38 MAPK in cultured smooth muscle cells, and this effect was shown to be pertussis toxin (PTX) sensitive (33). It is also known that PTX-sensitive G_i protein is involved in adenosine A₁ receptor antiadrenergic effects and adenosine-induced cardiac preconditioning (3, 21). It remains unknown whether the modulation of PP2a by adenosine A₁ receptor activation involves a G_i protein. Evidence is available indicating that PTX inhibits PP2a-like activity in PC12 cells (8), and angiotensin II receptor activation works through a G_i protein-dependent mechanism to increase PP2a activity in cultured neuronal cells (17). Thus we hypothesized that adenosine A₁ receptor activation works through a G_i protein to activate p38 MAPK and, in turn, to activate PP2a in cardiomyocytes.

Activation of G_i protein increases cGMP in ventricular myocytes (12, 30). This has been extensively studied in the ability of muscarinic receptors to activate G_i and cause an increase in cellular cGMP (12, 30). Adenosine A₁ receptor activation has been shown to increase cGMP accumulation in atrial myocytes (37) and atrioventricular nodal cells (26, 43) but not in ventricular myocytes (2, 5). However, the adenosine A₁ receptor agonist R-phenylisopropyladenosine, at relatively high concentrations, can inhibit cGMP phosphodiesterase in ventricular myocytes (28). Thus we investigated the possible link between cGMP and adenosine A₁ receptor activation in rat ventricular myocytes. Finally, cGMP-dependent activation of p38 MAPK has been shown in isolated cardiomyocytes and fibroblasts (4, 20), and a link between cGMP and protein phosphatase has been suggested in cardiomyocytes (29, 35). Taken together, these studies led us to hypothesize that the adenosine A₁ receptor induces cardiac PP2a translocation/activation through a G_i-cGMP-p38 MAPK signaling pathway in ventricular myocytes.

	MATERIALS AND METHODS

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Enzymatic isolation of rat ventricular myocytes. Experiments using animals were reviewed and approved by the Animal Care and Use Committee of the University of Tennessee Health Sciences Center.

Ventricular myocytes were isolated according to the protocol of Lester et al. (22) with slight modifications. Briefly, hearts were removed from female Wistar rats (200–250 g) anesthetized by isoflurane inhalation. The aorta was cannulated, and the heart was mounted on a Langendorff apparatus. Residual blood in the heart was washed out with Ringer solution containing 0.5 mM EGTA for 5 min. Ringer solution contained (in mM) 25 HEPES (pH 7.4), 1.2 MgCl₂, 4.8 KCl, 118 NaCl, 1 KH₂PO4, 5 pyruvate, and 11 glucose. The heart was then perfused with Ringer solution containing type II collagenase (1 mg/ml, Worthington Biochemical; Lakewood, NJ) for 12–15 min. After collagenase perfusion, the heart was removed from the perfusing apparatus, trimmed of atria and great vessels, cut into small pieces, and incubated in fresh Ringer solution without collagenase for 10 min. The cells were then dissociated by gentle trituration, filtered through a nylon mesh, and resuspended in oxygenated Ringer solution containing 1.25 mM CaCl₂ and 0.1% BSA. Cell suspensions containing <60% rod-shaped viable ventricular myocytes were discarded.

Preparation of cell fractions. Cell fractions of ventricular myocytes were prepared by the digitionin permeabilization method described by Whisler et al. (40) with some modifications. Briefly, after the various treatments, ventricular myocytes were centrifuged, and cell pellets were resuspended in ice-cold 0.05% digitonin permeabilization buffer containing (in mM) 10 HEPES (pH 7.4), 10 KCl, 1.5 MgCl₂, 1 dithiothreitol, 1 sodium orthovanadate, 1 benzamidine, 1 leupeptin, and 1 phenylmethylsulfonyl fluoride. The cells were gently mixed in permeabilization buffer for 5 min on ice, aspirated repeatedly through a 25-gauge needle, and centrifuged at 12,000 g for 5 min at 4°C. The resulting supernatant was designated the cytosolic fraction. The pellet was then dissolved in the same buffer supplemented with 1% Triton X-100 and left on ice for 20 min. Subsequent centrifugation at 12,000 g for 15 min at 4°C produced a supernatant containing PP2a solubilized by Triton X-100, which was designated the particulate fraction. PP2a content in the insoluble pellet was negligible as determined by Western blot analysis (date not shown).

Analysis of PP2a translocation. PP2a translocation studies were performed as previously described (24). Ventricular myocytes were pretreated with vehicle, 5 or 25 µM SB-203580, 1 µM SP-600125, 100 µM LY-83583, 1 µM NS-2028, or 50 µM 8-(4-chlorophenylthio)guanosine 3',5'-cyclic mono-phosphothioate-Rp-isomer (Rp-8-pCPT-cGMPS) for 30 min, followed by 1 µM CPA for 5 min. In another set of experiments, the cells were treated with 100 µM dibutyryl-cGMP for 0, 1, 5, 10, and 30 min. All cells were then centrifuged and fractionated into cytosolic and particulate fractions (see Preparation of cell fractions). Fractions were incubated with 0.1 N NaOH at 30°C for 30 min to fully demethylate PP2a-C (6). After NaOH treatment, samples were neutralized with HCl and heated at 95°C for 5 min. Proteins were separated by SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes. Western blotting was carried out using an antibody to PP2a-C (1:1,000 dilution, catalog number 05-421, Upstate Biotechnology), a horseradish peroxidase-conjugated secondary antibody (1:4,000 dilution, catalog number A3682, Sigma; St. Louis, MO) and visualized with enhanced chemiluminescence (Perkin Elmer Life Sciences; Boston, MA). Blots were also stained with Coomassie blue or Ponceau S for an assessment of protein loading. Densities of the PP2a-reactive band were determined with NIH Image software (public domain). Data were normalized to protein load and corresponding controls in each experiment.

Measurement of p38 MAPK phosphorylation. Assessment of the phosphorylation state of p38 MAPK in ventricular myocytes was accomplished by Western blotting. Isolated ventricular myocytes were pretreated with 2.0 µg/ml PTX for 3 h or for 30 min with 25 µM SB-203580, 100 µM LY-83583, 1 µM NS-2028, or 50 µM Rp-8-pCPT-cGMPS. Cells were then exposed to 1 µM CPA or vehicle for 5 min and lysed in SDS sample buffer. In another set of experiments, cells were treated with 100 µM dibutyryl-cGMP for 0, 1, 5, 10, and 30 min and lysed in SDS sample buffer. Samples were heated for 5 min at 95°C, separated by SDS-PAGE, and transferred to PVDF membranes. Western blotting was performed with polyclonal anti-phospho-p38 MAPK (Thr¹⁸⁰/Tyr¹⁸²) antibody (1:1,000 dilution, catalog number 9211, New England Biolabs; Beverly, MA) and horseradish peroxidase-conjugated secondary antibody (1:16,000 dilution, catalog number A0545, Sigma). Phospho-p38 MAPK-reactive bands were visualized with enhanced chemiluminescence. Signals were quantitated with NIH Image software and normalized for protein load and corresponding controls in each experiment.

Determination of cardiac protein phosphorylation. Changes in the phosphorylation state of cardiac proteins were determined by ³²P autoradiography as described previously (24). Isolated myocytes were incubated in Ringer solution containing 200 µCi/ml [³²P]orthophosphate (NEN) and 1 mM CaCl₂ for 1 h at room temperature. Ventricular myocytes were pretreated with 2.0 µg/ml PTX for 3 h or 25 µM SB-203580 for 30 min. Cells were then untreated or treated with 1 µM CPA, CPA plus 10 nM isoproterenol (Iso), or Iso alone for 5 min. All drug solutions were prepared in 1 mM CaCl₂-Ringer solution containing 100 µM sodium metabisulfate to protect Iso from oxidation and 10 U/ml adenosine deaminase to avoid inference from endogenous adenosine. Reactions were quenched by the addition of SDS sample buffer. All samples were heated for 5 min at 95°C, and proteins were resolved by 17% SDS-PAGE. Gels were stained with Coomassie blue, dried between cellophane, and subjected to autoradiography with X-OMAT film (Eastman Kodak; Rochester, NY). Exposure times ranged from 12 to 48 h. Densities were determined with NIH Image software. Data were normalized to protein load and to the corresponding control myocyte response.

Statistical analysis. All data were analyzed by two-way ANOVA and the appropriate post hoc test. All values are expressed as means ± SE, and P < 0.05 was chosen to indicate statistical significance.

	RESULTS

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
p38 MAPK inhibition blocks adenosine A₁ receptor-induced PP2a-C translocation. The effect of the adenosine A₁ receptor agonist CPA on the subcellular distributions of PP2a-C was determined in ventricular myocytes in the presence and absence of the p38 MAPK inhibitor SB-203580 or the JNK inhibitor SP-600125. CPA caused a significant increase in the level of PP2a-C in the particulate fraction that was blocked by 5 µM SB-203580 but not by 1 µM SP-600125 (Fig. 1). SB-203580 and SP-600125 in the absence of CPA had no effect on PP2a-C subcellular distribution.

View larger version (38K): [in this window] [in a new window]   Fig. 1. Catalytic unit of protein phosphatase 2a (PP2a-C) translocation after adenosine A1 receptor activation in the presence and absence of p38 MAPK or JNK inhibition. Ventricular myocytes were pretreated with 5 µM SB-203580 (SB; a p38 MAPK inhibitor) or 1 µM SP-600125 (SP; a JNK inhibitor), followed by 1 µM N6-cyclopentyladenosine (CPA; an adenosine A1 receptor agonist) or vehicle. Cells were then fractionated, and the levels of PP2a-C in the particulate fraction were determined with Western blot analysis (see MATERIALS AND METHODS). A representative Western blot (top) and cumulative results (bottom) are presented. Data are expressed relative to control (Con) and are means ± SE of 4 independent experiments. *P < 0.05 compared with Con.

Adenosine A₁ receptor-G_i-cGMP pathway activates p38 MAPK in ventricular myocytes. The ability of CPA to activate p38 MAPK was determined using phospho-p38 MAPK-specific antibodies. As shown in Fig. 2, CPA stimulated p38 MAPK phosphorylation. The response was maximal at 5 min and declined thereafter. Phosphorylation of p38 MAPK remained elevated at 30 min (longest time tested).

View larger version (18K): [in this window] [in a new window]   Fig. 2. Effect of adenosine A1 receptor activation on p38 MAPK phosphorylation in ventricular myocytes. A representative Western blot (top) and cumulative results (bottom) are presented. Ventricular myocytes were treated with 1 µM CPA for the times indicated. Results were normalized for protein load and expressed relative to Con. Data are means ± SE of 4 independent experiments. *P < 0.05 compared with untreated cells (i.e., time = 0 min).

To establish whether CPA-induced p38 MAPK activation involves PTX-sensitive G_i protein and guanylyl cyclase, we determined the effect of PTX, the soluble guanylyl cyclase inhibitor NS-2028, and the cell-permeable inactive cGMP analog Rp-8-pCPT-cGMPS on CPA-induced p38 MAPK phosphorylation. PTX and SB-203580 abolished the effect of CPA on p38 MAPK phosphorylation (Fig. 3A). NS-2028 and Rp-8-pCPT-cGMPS also blocked the effect of CPA to phosphorylate p38 MAPK (Fig. 3B). Additional studies revealed that the guanylyl cyclase inhibitor LY-83583 (100 µM) also blocked the effect of CPA on p38 MAPK phosphorylation (data not shown). PTX, SB-203580, LY-83583, NS-2028 or Rp-8-pCPT-cGMPS in the absence of CPA had no effect on p38 MAPK phosphorylation. To further confirm the role of guanylyl cyclase in CPA-induced p38 MAPK activation, we treated cadiomyocytes with the membrane-permeable cGMP analog dibutyryl-cGMP. As shown in Fig. 4, dibutyryl-cGMP stimulated p38 MAPK phosphorylation as early as 1 min, peaked at 10 min, and remained elevated for at least 30 min.

View larger version (28K): [in this window] [in a new window]   Fig. 3. p38 MAPK phosphorylation after exposure to 1 µM CPA, 2 µg/ml pertussis toxin (PTX), 25 µM SB, 1 µM NS-2028 (NS), and 50 µM Rp-8-pCPT-cGMPS (Rp) in ventricular myocytes. Ventricular myocytes were pretreated to inhibit Gi proteins (PTX), p38 MAPK (SB), cGMP signaling (NS and Rp), or vehicle (Con). Cells were then treated with the adenosine A1 receptor agonist CPA or vehicle. *P < 0.05 compared with Con.

View larger version (16K): [in this window] [in a new window]   Fig. 4. Effect of 100 µM dibutyryl-cGMP on p38 MAPK phosphorylation in cardiomyocytes. A representative Western blot (top) and cumulative results (bottom) are presented. Results were normalized for protein load and expressed relative to untreated myocytes (i.e., time = 0 min). Data are means ± SE of 4 independent experiments. *P < 0.05 compared with untreated cells.

Adenosine A₁ receptor-induced PP2a-C translocation requires guanylyl cyclase activation. To investigate whether guanylyl cyclase is involved in CPA-induced PP2a-C translocation, the effect of CPA on the subcellular distribution of PP2a-C was examined in the presence of the soluble guanylyl cyclase inhibitor NS-2028 and the cell-permeable inactive cGMP analog Rp-8-pCPT-cGMPS. Both NS-2028 and Rp-8-pCPT-cGMPS blocked CPA-induced PP2a-C translocation, whereas NS-2028 or Rp-8-pCPT-cGMPS in the absence of CPA had no effect (Fig. 5). The effect of dibutyryl-cGMP on PP2a-C subcellular distribution was also investigated. Dibutyryl-cGMP caused a translocation of PP2a-C to the particulate fraction of ventricular myocytes (Fig. 6). This translocation occurred as early as 1 min, peaked at 10 min, and lasted for at least 30 min.

View larger version (32K): [in this window] [in a new window]   Fig. 5. PP2a-C translocation after adenosine A1 receptor activation in the presence and absence of guanylyl cyclase inhibition. Cumulative results for PP2a-C in the particulate fraction are shown. Ventricular myocytes were pretreated with 1 µM NS (a soluble guanylyl cyclase inhibitor) and 50 µM Rp (a protein kinase G inhibitor) or vehicle, followed by 1 µM CPA. Data are expressed relative to Con and are means ± SE of 3 independent experiments. *P < 0.05 compared with Con.

View larger version (16K): [in this window] [in a new window]   Fig. 6. Effect of 100 µM dibutyryl-cGMP on localization of PP2a-C to the particulate fraction in ventricular myocytes. A representative Western blot for PP2a-C in the particulate fraction (top) and cumulative quantitative results (bottom) are presented. Data are expressed relative to untreated myocytes (i.e., time = 0 min) and are means ± SE of 4 independent experiments. *P < 0.05 compared with untreated cells.

Adenosine A₁ receptor activation dephosphorylates cardiac proteins through PTX-sensitive G protein and p38 MAPK. We (24) have previously demonstrated that CPA induced a dephosphorylation of the cardiac regulatory proteins phospholamban (PLB) and troponin I (TnI) in the presence and absence of -adrenergic stimulation and that the PP2a inhibitor okadaic acid blocked this effect. In the present study, we investigated the role of PTX-sensitive G protein and p38 MAPK in CPA-induced dephosphorylations of PLB and TnI by ³²P autoradiography. CPA caused a decrease in both basal and Iso-stimulated PLB and TnI phosphorylation in ventricular myocytes (Fig. 7, -PTX). This effect of CPA on PLB and TnI phosphorylation was abolished by pretreatment of cardiomyocytes with PTX (Fig. 7, +PTX). PTX did not significantly affect either basal (control) or Iso-stimulated PLB or TnI phosphorylation (Fig. 7). The effect of CPA on PLB and TnI phosphorylations in the presence and absence of the p38 MAPK inhibitor SB-203580 was also examined. As shown in Fig. 8, the CPA-induced dephosphorylations of PLB and TnI, with CPA alone or with Iso + CPA treatment, were attenuated by SB-203580. SB-203580 alone did not significantly change the phosphorylation state of PLB or TnI (Fig. 8, control ± SB).

View larger version (19K): [in this window] [in a new window]   Fig. 7. 32P incorporation into phospholamban (PLB; A) and troponin I (TnI; B) in the presence (+) and absence (-) of 2 µg/ml PTX. Ventricular myocytes were preteated with PTX (a Gi protein inhibitor) or vehicle, followed by 1 µM CPA (an adenosine A1 receptor agonist) in the presence or absence of the -adrenergic receptor agonist isoproterenol (Iso). Data are means ± SE from 5 isolations. *P < 0.05 compared with Con without PTX; #P < 0.05 compared with Iso without PTX.

View larger version (18K): [in this window] [in a new window]   Fig. 8. 32P incorporation into PLB (A) and TnI (B) in the presence (+) and absence (-) of p38 MAPK inhibition. Ventricular myocytes were preteated with 25 µM SB (a p38 MAPK inhibitor) or vehicle, followed by 1 µM CPA (an adenosine A1 receptor agonist) in the presence or absence of the -adrenergic receptor agonist Iso (100 nM). Data are means ± SE from 5 isolations. *P < 0.05 compared with Con without SB; #P < 0.05 compared with Iso without SB.

	DISCUSSION

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Adenosine A₁ receptor activation causes PP2a translocation and activation, leading to an antiadrenergic effect in the heart (24). In the present study, we investigated the signaling pathway involved in the translocation/activation of PP2a by adenosine A₁ receptors in ventricular myocytes. We found that CPA-induced PP2a translocation was blocked by the p38 MAPK inhibitor SB-203580 (Fig. 1). CPA also increased phosphorylation of p38 MAPK, and this effect was abolished by PTX, the soluble guanylyl cyclase inhibitor NS-2028, and the protein kinase G inhibitor Rp-8-pCPT-cGMPS (Figs. 2 and 3). The guanylyl cyclase activator dibutyryl-cGMP caused p38 MAPK phosphorylation and PP2a translocation (Figs. 4 and 6), mimicking the effect of CPA. CPA-induced PP2a translocation was also blocked by NS-2028 and Rp-8-pCPT-cGMPS (Fig. 5). Finally, we showed that CPA-induced dephosphorylations of TnI and PLB were blocked by PTX and attenuated by SB-203580 (Fig. 7 and 8). These results suggest that CPA-induced PP2a translocation requires p38 MAPK activation and involves both a PTX-sensitive G_i protein and guanylyl cyclase.

The regulatory mechanisms controlling cellular PP2a activity are not fully understood. Evidence suggests that PP2a can be regulated by posttranslational modifications of PP2a-C and regulatory subunits, association of PP2a-C with regulatory proteins, and subcellular localization of the PP2a holoenzyme (18). Translocation of PP2a to specific subcellular locations provides a means of increasing PP2a activity in a local microenvironment with specific PP2a substrates. In the present study, we confirmed that adenosine A₁ receptor activation caused translocation of PP2a to the particulate fraction in ventricular myocytes (24). In addition, CPA-induced PP2a translocation could be blocked by the p38 MAPK inhibitor SB-203580. SB-203580 can inhibit other kinases, such as JNK (10). To confirm that the linkage between the adenosine A₁ receptor and PP2a translocation is through p38 MAPK, the effect of CPA on PP2a translocation was examined in the presence of two doses of SB-302580 (5 and 25 µM) and with the JNK inhibitor SP-600125. SB-302580 at 5 and 25 µM both blocked CPA-induced PP2a translocation, whereas SP-600125 had no effect. This suggests a role of p38 MAPK in the modulation of PP2a translocation. This finding is consistent with the study of Westermarck et al. (39) showing that p38 MAPK activation stimulates PP1/2a activity and inhibits the phosphorylation of MEK1/2 in human skin fibroblasts, and work by Avdi et al. (1) demonstrating p38 MAPK-dependent PP2a activation in human neutrophils. How p38 MAPK affects PP2a translocation/activation is still unknown. However, phosphorylation of the PP2a regulatory subunit has been shown to promote in vitro activity (41), and the regulatory subunit is known to target PP2a to specific subcellular localizations and determines substrate specificity (7, 27, 36). Thus it is possible that CPA induces PP2a translocation through p38 MAPK-dependent phosphorylation of specific PP2a regulatory subunits.

Although rapid phosphorylation and activation of p38 MAPK by adenosine has been demonstrated in the perfused rat heart (15), it is not known whether p38 MAPK is activated by adenosine A₁ receptors in ventricular myocytes. The present study demonstrated that adenosine A₁ receptor activation with CPA caused a rapid phosphorylation of p38 MAPK in cardiomyocytes, and this effect was blocked by PTX. This suggests the involvement of a PTX-sensitive G_i protein. This result is consistent with similar observations in smooth muscle cells (33). Moreover, G_i protein-dependent p38 MAPK activation has been demonstrated in cultured cardiomyocytes with M₂ muscarinic receptor or ₂-adrenergic receptor stimulation (11). No other studies have demonstrated a role of G_i proteins in the modulation of PP2a activation in cardiomyocytes, although G_i-dependent PP2a activation occurs in neuronal cells and PC12 cells (8, 17).

In the present study, CPA-induced p38 MAPK activation and PP2a translocation were blocked by the soluble guanylyl cyclase inhibitor NS-2028 and LY-83583 and the protein kinase G inhibitor Rp-8-pCPT-cGMPS. This suggests a role for cGMP. However, adenosine does not appear to increase total cGMP levels in ventricular myocytes (2, 5). One possible explanation of this apparent discrepancy is that adenosine A₁ receptor activation increases cGMP in select subcellular compartments, and this increase is not measurable by the whole cell cGMP assay. The present study also demonstrated that activation of guanylyl cyclase with dibutyryl-cGMP mimicked the effects of CPA to increase p38 MAPK phosphorylation and caused PP2a translocation. Together, these findings suggest that adenosine A₁ receptor activation, via G_i protein and guanylyl cyclase, activates p38 MAPK. Activation of p38 MAPK appears to promote PP2a translocation in ventricular myocytes.

Our previous study (24) demonstrated that CPA treatment of ventricular myocytes caused a significant decrease in basal as well as -adrenergic-stimulated phosphorylation of TnI and PLB. This effect was adenosine A₁ receptor and PP2a dependent (24). Others have also demonstrated that TnI and PLB are substrates of PP2a (19, 32, 42). Adenosine A₁ receptor-dependent PP2a activation, by itself, reduced myocardial protein phosphorylation with no significant changes in cardiac function (24). In the presence of -adrenergic stimulation, adenosine A₁ receptor-dependent PP2a activation and subsequent dephosphorylation of myocardial proteins leads to an attenuation of the -adrenergic functional effects (24). A decrease in the contractile response of myocardial preparations has also been reported with G_i protein, cGMP, and p38 MAPK activation (3, 23, 38). Thus modulation of cardiac function by adenosine A₁ receptor-dependent PP2a activation may involve concerted activation of G_i protein, cGMP, and p38 MAPK.

In summary, the present study strongly suggests that cardiac regulatory proteins can be dephosphorylated by PP2a through an adenosine A₁ receptor-dependent G_i-cGMP-p38 MAPK pathway. This novel pathway suggests a role for PP2a in the acute modulation of cardiac function.

	ACKNOWLEDGMENTS

 
This study was supported by National Heart, Lung, and Blood Institute Grant HL-48839 and by an American Heart Established Investigatorship (to P. A. Hofmann).

	FOOTNOTES

 

Address for reprint requests and other correspondence: P. A. Hofmann, Dept. of Physiology, Univ. of Tennessee Health Science Center, 894 Union Ave., Memphis, TN 38163 (E-mail: phofmann{at}physio1.utmem.edu).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

	REFERENCES

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Avdi NJ, Malcolm KC, Nick JA, and Worthen GS. A role for protein phosphatase-2a in p38 mitogen-activated protein kinase-mediated regulation of the c-Jun NH₂-terminal kinase pathway in human neutrophils. J Biol Chem 277: 40687-40696, 2002.[Abstract/Free Full Text]
2. Bohm M, Bruckner R, Hackbarth I, Haubitz B, Linhart R, Meyer W, Schmidt B, Schmitz W, and Scholz H. Adenosine inhibition of catecholamine-induced increase in force of contraction in guinea-pig atrial and ventricular heart preparations. Evidence against a cyclic AMP- and cyclic GMP-dependent effect. J Pharmacol Exp Ther 230: 483-492, 1984.[Abstract/Free Full Text]
3. Brown LA, Humphrey SM, and Harding SE. The anti-adrenergic effect of adenosine and its blockade by pertussis toxin: a comparative study in myocytes isolated from guinea-pig, rat and failing human hearts. Br J Pharmacol 101: 484-488, 1990.[Web of Science][Medline]
4. Browning DD, McShane MP, Marty C, and Ye RD. Nitric oxide activation of p38 mitogen-activated protein kinase in 293T fibroblasts requires cGMP-dependent protein kinase. J Biol Chem 275: 2811-2816, 2000.[Abstract/Free Full Text]
5. Bruckner R, Fenner A, Meyer W, Nobis TM, Schmitz W, and Scholz H. Cardiac effects of adenosine and adenosine analogs in guinea-pig atrial and ventricular preparations: evidence against a of cyclic AMP and cyclic GMP. J Pharmacol Exp Ther 234: 766-774, 1985.[Abstract/Free Full Text]
6. Bryant JC, Westphal RS, and Wadzinski BE. Methylated C-terminal leucine residue of PP2A catalytic subunit is important for binding of regulatory Balpha subunit. Biochem J 339: 241-246, 1999.[Web of Science][Medline]
7. Cegielska A, Shaffer S, Derua R, Goris J, and Virshup DM. Different oligomeric forms of protein phosphatase 2A activate and inhibit simian virus 40 DNA replication. Mol Cell Biol 14: 4616-4623, 1994.[Abstract/Free Full Text]
8. Chen F, Vu ND, and Wagner PD. Pertussis toxin modification of PC12 cells inhibits a protein phosphatase 2A-like phosphatase. J Neurochem 71: 248-257, 1998.[Web of Science][Medline]
9. Chen J, Martin BL, and Brautigan DL. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science 257: 1261-1264, 1992.[Abstract/Free Full Text]
10. Clerk A and Sugden PH. The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs). FEBS Lett 426: 93-96, 1998.[Web of Science][Medline]
11. Communal C, Colucci WS, and Singh K. p38 mitogen-activated protein kinase pathway protects adult rat ventricular myocytes against beta-adrenergic receptor-stimulated apoptosis. Evidence for Gi-dependent activation. J Biol Chem 275: 19395-19400, 2000.[Abstract/Free Full Text]
12. Endoh M, Maruyama M, and Iijima T. Attenuation of muscarinic cholinergic inhibition by islet-activating protein in the heart. Am J Physiol Heart Circ Physiol 249: H309-H320, 1985.[Abstract/Free Full Text]
13. Guo H, Reddy SA, and Damuni Z. Purification and characterization of an autophosphorylation-activated protein serine threonine kinase that phosphorylates and inactivates protein phosphatase 2A. J Biol Chem 268: 11193-11198, 1993.[Abstract/Free Full Text]
14. Gupta RC, Neumann J, Boknik P, and Watanabe AM. M₂-specific muscarinic cholinergic receptor-mediated inhibition of cardiac regulatory protein phosphorylation. Am J Physiol Heart Circ Physiol 266: H1138-H1144, 1994.[Abstract/Free Full Text]
15. Haq SE, Clerk A, and Sugden PH. Activation of mitogen-activated protein kinases (p38-MAPKs, SAPKs/JNKs and ERKs) by adenosine in the perfused rat heart. FEBS Lett 434: 305-308, 1998.[Web of Science][Medline]
16. Herzig S, Meier A, Pfeiffer M, and Neumann J. Stimulation of protein phosphatases as a mechanism of the muscarinic-receptor-mediated inhibition of cardiac L-type Ca²⁺ channels. Pflügers Arch 429: 531-538, 1995.[Web of Science][Medline]
17. Huang XC, Richards EM, and Sumners C. Mitogen-activated protein kinases in rat brain neuronal cultures are activated by angiotensin II type 1 receptors and inhibited by angiotensin II type 2 receptors. J Biol Chem 271: 15635-15641, 1996.[Abstract/Free Full Text]
18. Janssens V and Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 353: 417-439, 2001.[Web of Science][Medline]
19. Jaquet K, Thieleczek R, and Heilmeyer LM Jr. Pattern formation on cardiac troponin I by consecutive phosphorylation and dephosphorylation. Eur J Biochem 231: 486-490, 1995.[Web of Science][Medline]
20. Kim SO, Xu Y, Katz S, and Pelech S. Cyclic GMP-dependent and -independent regulation of MAP kinases by sodium nitroprusside in isolated cardiomyocytes. Biochim Biophys Acta 1496: 277-284, 2000.[Medline]
21. Lasley RD and Mentzer RM Jr. Pertussis toxin blocks adenosine A₁ receptor mediated protection of the ischemic rat heart. J Mol Cell Cardiol 25: 815-821, 1993.[Web of Science][Medline]
22. Lester JW, Gannaway KF, Reardon RA, Koon LD, and Hofmann PA. Effects of adenosine and protein kinase C stimulation on mechanical properties of rat cardiac myocytes. Am J Physiol Heart Circ Physiol 271: H1778-H1785, 1996.[Abstract/Free Full Text]
23. Liao P, Wang SQ, Wang S, Zheng M, Zheng M, Zhang SJ, Cheng H, Wang Y, and Xiao RP. p38 Mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes. Circ Res 90: 190-196, 2002.[Abstract/Free Full Text]
24. Liu Q and Hofmann PA. Antiadrenergic effects of adenosine A₁ receptor-mediated protein phosphatase 2a activation in the heart. Am J Physiol Heart Circ Physiol 283: H1314-H1321, 2002.[Abstract/Free Full Text]
25. Ludowyke RI, Holst J, Mudge LM, and Sim AT. Transient translocation and activation of protein phosphatase 2A during mast cell secretion. J Biol Chem 275: 6144-6152, 2000.[Abstract/Free Full Text]
26. Martynyuk AE, Kane KA, Cobbe SM, and Rankin AC. Nitric oxide mediates the anti-adrenergic effect of adenosine on calcium current in isolated rabbit atrioventricular nodal cells. Pflügers Arch 431: 452-457, 1996.[Web of Science][Medline]
27. McCright B, Rivers AM, Audlin S, and Virshup DM. The B56 family of protein phosphatase 2A (PP2A) regulatory subunits encodes differentiation-induced phosphoproteins that target PP2A to both nucleus and cytoplasm. J Biol Chem 271: 22081-22089, 1996.[Abstract/Free Full Text]
28. Meyer W, Nose M, Schmitz W, and Scholz H. Adenosine and adenosine analogs inhibit phosphodiesterase activity in the heart. Naunyn Schmiedebergs Arch Pharmacol 328: 207-209, 1984.[Web of Science][Medline]
29. Mope L, McClellan GB, and Winegrad S. Calcium sensitivity of the contractile system and phosphorylation of troponin in hyperpermeable cardiac cells. J Gen Physiol 75: 271-282, 1980.[Abstract/Free Full Text]
30. Mubagwa K, Shirayama T, Moreau M, and Pappano AJ. Effects of PDE inhibitors and carbachol on the L-type Ca current in guinea pig ventricular myocytes. Am J Physiol Heart Circ Physiol 265: H1353-H1363, 1993.[Abstract/Free Full Text]
31. Narayan P, Mentzer RM Jr, and Lasley RD. Phosphatase inhibitor cantharidin blocks adenosine A₁ receptor anti-adrenergic effect in rat cardiac myocytes. Am J Physiol Heart Circ Physiol 278: H1-H7, 2000.[Abstract/Free Full Text]
32. Neumann J, Mass R, Boknik P, Jones LR, Zimmermann N, and Scholz H. Pharmacological characterization of protein phosphatase activities in preparations from failing human hearts. J Pharmacol Exp Ther 289: 188-193, 1999.[Abstract/Free Full Text]
33. Robinson AJ and Dickenson JM. Regulation of p42/p44 MAPK and p38 MAPK by the adenosine A(1) receptor in DDT(1)MF-2 cells. Eur J Pharmacol 413: 151-161, 2001.[Web of Science][Medline]
34. Ruvolo PP, Clark W, Mumby M, Gao F, and May WS. A functional role for the B56 alpha-subunit of protein phosphatase 2A in ceramide-mediated regulation of Bcl2 phosphorylation status and function. J Biol Chem 277: 22847-22852, 2002.[Abstract/Free Full Text]
35. Shen JB and Pappano AJ. On the role of phosphatase in regulation of cardiac L-type calcium current by cyclic GMP. J Pharmacol Exp Ther 301: 501-506, 2002.[Abstract/Free Full Text]
36. Sontag E, Nunbhakdi-Craig V, Bloom GS, and Mumby MC. A novel pool of protein phosphatase 2A is associated with microtubules and is regulated during the cell cycle. J Cell Biol 128: 1131-1144, 1995.[Abstract/Free Full Text]
37. Sterin-Borda L, Gomez RM, and Borda E. Role of nitric oxide/cyclic GMP in myocardial adenosine A₁ receptor-inotropic response. Br J Pharmacol 135: 444-450, 2002.[Web of Science][Medline]
38. Wegener JW, Nawrath H, Wolfsgruber W, Kuhbandner S, Werner C, Hofmann F, and Feil R. cGMP-dependent protein kinase I mediates the negative inotropic effect of cGMP in the murine myocardium. Circ Res 90: 18-20, 2002.[Abstract/Free Full Text]
39. Westermarck J, Li SP, Kallunki T, Han J, and Kahari VM. p38 mitogen-activated protein kinase-dependent activation of protein phosphatases 1 and 2A inhibits MEK1 and MEK2 activity and collagenase 1 (MMP-1) gene expression. Mol Cell Biol 21: 2373-2383, 2001.[Abstract/Free Full Text]
40. Whisler RL, Goyette MA, Grants IS, and Newhouse YG. Sublethal levels of oxidant stress stimulate multiple serine/threonine kinases and suppress protein phosphatases in Jurkat T cells. Arch Biochem Biophys 319: 23-35, 1995.[Web of Science][Medline]
41. Xu Z and Williams BR. The B56alpha regulatory subunit of protein phosphatase 2A is a target for regulation by double-stranded RNA-dependent protein kinase PKR. Mol Cell Biol 20: 5285-5299, 2000.[Abstract/Free Full Text]
42. Zhang T, Johnson EN, Gu Y, Morissette MR, Sah VP, Gigena MS, Belke DD, Dillmann WH, Rogers TB, Schulman H, Ross J Jr, and Brown JH. The cardiac-specific nuclear delta(B) isoform of Ca²⁺/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity. J Biol Chem 277: 1261-1267, 2002.[Abstract/Free Full Text]
43. Zima A, Martynyuk AE, Seubert CN, Morey TE, Sumners C, Cucchiara RF, and Dennis DM. Antagonism of the positive dromotropic effect of isoproterenol by adenosine: role of nitric oxide, cGMP-dependent cAMP-phosphodiesterase and protein kinase G. J Mol Cell Cardiol 32: 1609-1619, 2000.[Web of Science][Medline]

This article has been cited by other articles:

				M. Kurdi and G. W. Booz JAK redux: a second look at the regulation and role of JAKs in the heart Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1545 - H1556. [Abstract] [Full Text] [PDF]

				I. Szokodi, R. Kerkela, A.-M. Kubin, B. Sarman, S. Pikkarainen, A. Konyi, I. G. Horvath, L. Papp, M. Toth, R. Skoumal, et al. Functionally Opposing Roles of Extracellular Signal-Regulated Kinase 1/2 and p38 Mitogen-Activated Protein Kinase in the Regulation of Cardiac Contractility Circulation, October 14, 2008; 118(16): 1651 - 1658. [Abstract] [Full Text] [PDF]

				P. J. Leary, S. Rajasekaran, R. R. Morrison, E. I. Tuomanen, T. K. Chin, and P. A. Hofmann A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2775 - H2784. [Abstract] [Full Text] [PDF]

				M. R. Junttila, S.-P. Li, and J. Westermarck Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival FASEB J, April 1, 2008; 22(4): 954 - 965. [Abstract] [Full Text] [PDF]

				C. Ballard-Croft, A. C. Locklar, B. J. Keith, R. M. Mentzer Jr, and R. D. Lasley Oxidative stress and adenosine A1 receptor activation differentially modulate subcellular cardiomyocyte MAPKs Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H263 - H271. [Abstract] [Full Text] [PDF]

				P. A. Hofmann, M. Israel, Y. Koseki, J. Laskin, J. Gray, A. Janik, T. W. Sweatman, and L. Lothstein N-Benzyladriamycin-14-valerate (AD 198): A Non-Cardiotoxic Anthracycline That Is Cardioprotective through PKC-{epsilon} Activation J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 658 - 664. [Abstract] [Full Text] [PDF]

				X. Cheng, J. Liu, M. Asuncion-Chin, E. Blaskova, J. P. Bannister, A. M. Dopico, and J. H. Jaggar A Novel CaV1.2 N Terminus Expressed in Smooth Muscle Cells of Resistance Size Arteries Modifies Channel Regulation by Auxiliary Subunits J. Biol. Chem., October 5, 2007; 282(40): 29211 - 29221. [Abstract] [Full Text] [PDF]

				K. A. Sheehan, Y. Ke, and R. J. Solaro p21-Activated kinase-1 and its role in integrated regulation of cardiac contractility Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2007; 293(3): R963 - R973. [Abstract] [Full Text] [PDF]

				M. E. Reichelt, L. Willems, J. N. Peart, K. J. Ashton, G. P. Matherne, M. R. Blackburn, and J. P. Headrick Heart/Cardiac Muscle: Modulation of ischaemic contracture in mouse hearts: a 'supraphysiological' response to adenosine Exp Physiol, January 1, 2007; 92(1): 175 - 185. [Abstract] [Full Text] [PDF]

				E. Y. Tan, C. L. Richard, H. Zhang, D. W. Hoskin, and J. Blay Adenosine downregulates DPPIV on HT-29 colon cancer cells by stimulating protein tyrosine phosphatase(s) and reducing ERK1/2 activity via a novel pathway Am J Physiol Cell Physiol, September 1, 2006; 291(3): C433 - C444. [Abstract] [Full Text] [PDF]

				A. K. Snabaitis, R. D'Mello, S. Dashnyam, and M. Avkiran A Novel Role for Protein Phosphatase 2A in Receptor-mediated Regulation of the Cardiac Sarcolemmal Na+/H+ Exchanger NHE1 J. Biol. Chem., July 21, 2006; 281(29): 20252 - 20262. [Abstract] [Full Text] [PDF]

				E. I. Tikh, R. A. Fenton, and J. G. Dobson Jr. Contractile effects of adenosine A1 and A2A receptors in isolated murine hearts Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H348 - H356. [Abstract] [Full Text] [PDF]

				R. D. Lasley, B. J. Keith, G. Kristo, Y. Yoshimura, and R. M. Mentzer Jr. Delayed adenosine A1 receptor preconditioning in rat myocardium is MAPK dependent but iNOS independent Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H785 - H791. [Abstract] [Full Text] [PDF]

				M. S. Gigena, A. Ito, H. Nojima, and T. B. Rogers A B56 regulatory subunit of protein phosphatase 2A localizes to nuclear speckles in cardiomyocytes Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H285 - H294. [Abstract] [Full Text] [PDF]

				C. Ballard-Croft, G. Kristo, Y. Yoshimura, E. Reid, B. J. Keith, R. M. Mentzer Jr., and R. D. Lasley Acute adenosine preconditioning is mediated by p38 MAPK activation in discrete subcellular compartments Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1359 - H1366. [Abstract] [Full Text] [PDF]

				E. Hersch, J. Huang, J. R. Grider, and K. S. Murthy Gq/G13 signaling by ET-1 in smooth muscle: MYPT1 phosphorylation via ETA and CPI-17 dephosphorylation via ETB Am J Physiol Cell Physiol, November 1, 2004; 287(5): C1209 - C1218. [Abstract] [Full Text] [PDF]

				Q. Liu and P. A. Hofmann Protein phosphatase 2A-mediated cross-talk between p38 MAPK and ERK in apoptosis of cardiac myocytes Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2204 - H2212. [Abstract] [Full Text] [PDF]

				R. Schulz and G. Heusch Connexin 43 and ischemic preconditioning Cardiovasc Res, May 1, 2004; 62(2): 335 - 344. [Abstract] [Full Text] [PDF]

				J. M. Metzger and M. V. Westfall Covalent and Noncovalent Modification of Thin Filament Action: The Essential Role of Troponin in Cardiac Muscle Regulation Circ. Res., February 6, 2004; 94(2): 146 - 158. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 285/1/H97    most recent 00956.2002v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (31) Citing Articles via Google Scholar Google Scholar Articles by Liu, Q. Articles by Hofmann, P. A. Search for Related Content PubMed PubMed Citation Articles by Liu, Q. Articles by Hofmann, P. A.